Patheon IncTSX: PTI

Patheon Improves North American and European Credit Facilities

· Issued by Patheon Inc via CNW
TORONTO, Dec. 22 /CNW/ - Patheon Inc. (TSX: PTI) today announced that it
has completed previously announced arrangements for new North American credit
facilities in the aggregate amount of US$290 million, and has negotiated new
credit facilities for its wholly owned subsidiary in Italy.
"In North America, we have replaced eight different facilities in three
jurisdictions with one agreement providing for two term loans and a revolving
facility. This simplified structure provides Patheon with long-term, flexible
and more tax-efficient funding for our North American operations," explained
Robert Tedford, Chief Executive Officer, Patheon Inc. "We expect that these
advantages will benefit our earnings going forward."
The new North American loans replace debt facilities in Patheon's wholly
owned subsidiaries in Puerto Rico assumed as part of the acquisition of MOVA
Pharmaceutical Corporation in December, 2004, a one-year bridge facility
provided by a group of lenders also at the time of the MOVA acquisition, and
debt of its Cincinnati subsidiary. The North American facilities comprise two
term loans in the aggregate amount of US$215 million and revolving facilities
in the aggregate amount of US$75 million. The term loans consist of a five-
year term loan in the amount of US$50 million and a six-year term loan in the
amount of US$165 million, both of which can be repaid at any time without
penalty. The new facilities are secured by the North American assets of
Patheon and its subsidiaries, including those in Puerto Rico. Royal Bank of
Canada and RBC Capital Markets, as Lead Arranger, syndicated these new credit
facilities to a group of financial institutions in Canada and the United
States and Puerto Rico.
Patheon's wholly owned Italian subsidiary also entered into a new debt
facility today. The new loan replaced four separate term loans it had with an
Italian bank with a new credit facility with the same bank. The new loan
aggregating 28.5 million euros matures in 2014 and has equal semi-annual
principal payments over the term of the nine-year loan. The new facility will
be secured by the assets of Patheon's Italian operations, and a parent
guarantee from Patheon Inc. in the amount of 15 million euros, which is a 10
million euro reduction from the level of parent company guarantees that
Patheon Inc. had provided under the prior facilities.
"These new credit facilities improve our debt arrangements and provide
stable debt financing for the next five years in North America and nine years
in Italy," concluded Mr. Tedford.

Patheon (TSX:PTI; www.patheon.com) is a leading global provider of drug
development and manufacturing services to the international pharmaceutical
industry. Patheon operates a network of 14 facilities in the United States,
Canada and Europe, employing more than 5,900 people and serving a client base
of 180 pharmaceutical and biotechnology companies.

This news release contains forward-looking statements with respect to
Patheon, including its business operations and strategy and financial
performance and condition. Although management believes that the expectations
reflected in such forward-looking statements are reasonable, such statements
involve risks and uncertainties. Actual results may differ materially from
those expressed or implied by such forward-looking statements. Factors that
could cause actual results to differ materially from expectations include, but
are not limited to, currency fluctuations, the level of outsourcing services
required by the pharmaceutical companies (and in particular our clients), the
impact of changes in pharmaceutical development and manufacturing regulations
and general economic and market factors (including inflation and changes in
laws) and other factors discussed in materials filed with applicable
securities regulatory authorities from time to time.
%SEDAR: 00001700E

Patheon Inc on 6ix

Earlier from Patheon

Later from Patheon

All Patheon news releases